Bayer expands its global network of incubators with the opening of the Bayer Co.Lab Berlin, welcoming MyoPax as its first resident. This Berlin-based start-up specializes in muscle regeneration therapies.

The Bayer Co. Lab Berlin is part of a global network of life science incubators located in key innovation centers, including Cambridge (USA), Kobe (Japan) and Shanghai (China).

The brand-new, state-of-the-art Berlin incubator will provide access to fully equipped facilities and tailored mentoring from Bayer to advance breakthroughs in cell and gene therapy and oncology.

'The investment underlines Bayer's commitment to creating a leading life science ecosystem for innovative therapies in Berlin. MyoPax, which specializes in stem cell and gene editing technologies to develop muscle regeneration therapies, is the first resident company in the Bayer Co. Lab Berlin', says the group.

Copyright (c) 2024 CercleFinance.com. All rights reserved.